{"entity":{"id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","aka":[],"tldr":"A phase 2 trial of Active Comparator in advanced solid tumours, run by MetaFines, now recruiting.","summary":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 is a phase 2 interventional study registered as NCT07168226 by MetaFines, with 135 participants planned, started 2026-05-08 and due to reach its primary completion in 2028-04-30. Interventions recorded: Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07168226","url":"https://clinicaltrials.gov/study/NCT07168226"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07168226","phase":"2","setting":"A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor","sponsor":"MetaFines","enrolled":135,"outcomes":[]},"route":"/trials/nct07168226/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}